400-920-2911 sales@csnpharm.cn
CAS No.: 603139-19-1
Synonyms: MK-0822;奥当卡替
Odanacatib is a potent, selective, and neutral inhibitor of cathepsin K (human/rabbit) with IC50 of 0.2 nM/1 nM, and demonstrated high selectivity versus off-target cathepsin B, L, S.
规格 | 价格 | 促销价格 | 库存 | 数量 |
---|
生物活性
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|---|---|---|---|---|
NCT00242476 | Vitamin D Deficiency | Phase 2 | Completed | - | - |
NCT00397683 | Osteoarthritis | Phase 2 | Terminated | - | United States, California ... more >> Call for Information Palm Desert, California, United States, 92260 Call for Information Pomona, California, United States, 91767 Call for Information Torrance, California, United States, 90505 Call for Information Upland, California, United States, 91786 United States, Florida Call for Information Coral Gables, Florida, United States, 33134 Call for Information Hialeah, Florida, United States, 33010 Call for Information South Miami, Florida, United States, 33143-0000 United States, New York Call for Information Rochester, New York, United States, 14168 Call for Information Rochester, New York, United States, 14609 Call for Information Rochester, New York, United States, 14618 United States, Pennsylvania Call for Information Norristown, Pennsylvania, United States, 19401 Call for Information Perkasie, Pennsylvania, United States, 18944 Chile Merck Sharp & Dohme (I.A.) Corp. Santiago, Chile, 6761641 Colombia Frosst Laboratories Inc. Bogota, Cundinamarca, Colombia Mexico Merck Sharp & Dohme De Mexico, S.A. De C.V. Mexico, D.f., Mexico, 1090 Poland MSD Polska Sp. z o.o. Dzial Medyczny Warszawa, Poland, 00-867 Collapse << |
NCT00112437 | Osteoporosis | Phase 2 | Completed | - | - |
实验方案
技术信息
CAS号 | 603139-19-1 | 储存条件 |
|
|||||||||||
分子式 | C25H27F4N3O3S | 运输 | 蓝冰 | |||||||||||
分子量 | 525.56 | 别名 | MK-0822;奥当卡替 | |||||||||||
溶解度 |
|
动物实验配方 |
|